Sign up for email alert when new content gets added: Sign up
Modern ideas about the nature of acute inflammatory processes in the lungs are focused on the leading significance of the etiology of the disease. The predominance of this concept defines etiotropic therapy as the basis for providing medical care to this category of patients. In fact, the causative agent of acute pneumonia in most patients remains unknown or the accuracy of its diagnosis is questionable.At the same time, the targeted use of etiotropic drugs is always delayed due to the delay in the results of microbiological diagnostics. Recently, these difficulties of etiotropic therapy have been compounded by an increase in the number of patients with viral lung inflammation and the lack of effective antiviral drugs.